Lanoconazole is a potent antifungal imidazole launched in Japan for the
treatment of dermal mycoses. Lanoconazole is reported to be an inhibitor of
ergosterol biosynthesis thus altering the ultra structure of the cell wall. It exhibits
potent antifungal activity against a wide range of pathogenic fungi including yeast,
dermatophytes, dermatiaceous fungi, dimorphic fungi, Aspergihs spp., Penici//ium
spp., and Candida spp., being particularly active against Trichophyton spp.. It is
considerably more potent than other agents of the same family such as bifonazole
and clotrimazole. Clinical efficacy was demonstrated by remarkable improvements
in skin symptoms of the patients with tinea pedis, tinea corporis and cruis,
candidiasis or tinea versicolor.
